<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722627</url>
  </required_header>
  <id_info>
    <org_study_id>AT-02A-001</org_study_id>
    <nct_id>NCT04722627</nct_id>
  </id_info>
  <brief_title>Study of AT-752 in Healthy Subjects</brief_title>
  <official_title>A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in&#xD;
      healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A First-in Human, Randomized, Double-blind, Placebo controlled Single and Multiple Ascending&#xD;
      Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy&#xD;
      Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events</measure>
    <time_frame>Day 6 for single dose or Day 12 for multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-752 of single and multiple ascending oral doses</measure>
    <time_frame>Day 1 for subjects receiving a single fasted dose; Days 1 and 7 for subjects receiving multiple doses</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-752 of single and multiple ascending oral doses</measure>
    <time_frame>Day 1 for subjects receiving a single fasted dose; Days 1 and 7 for subjects receiving multiple doses ]</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on Pharmacokinetics (PK) of AT-752 of a single oral dose</measure>
    <time_frame>Day 1 for subjects receiving a single fed dose]</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on Pharmacokinetics (PK) of AT-752 of a single oral dose</measure>
    <time_frame>Day 1 for subjects receiving a single fed dose ]</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>AT-752 250 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 administered orally, 250 mg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo -single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-752 500 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 administered orally, 500 mg single doses on Day 1 and Day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally on Day 1 and Day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-752 1000 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 administered orally, 1000 mg single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-752 1500 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 administered orally, 1500 mg single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-752 - 1000 mg QD multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 - administered orally, 1000 mg once daily (QD) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Administered once daily (QD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally once daily (QD) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-752 - 500 mg twice daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-752 administered orally, 500 mg twice daily (BID) for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Administered twice daily (BID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally twice daily (BID) for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-752</intervention_name>
    <description>Parallel Assignment</description>
    <arm_group_label>AT-752 - 1000 mg QD multiple doses</arm_group_label>
    <arm_group_label>AT-752 - 500 mg twice daily (BID)</arm_group_label>
    <arm_group_label>AT-752 1000 mg single dose</arm_group_label>
    <arm_group_label>AT-752 1500 mg single dose</arm_group_label>
    <arm_group_label>AT-752 250 mg single dose</arm_group_label>
    <arm_group_label>AT-752 500 mg single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Parallel Assignment</description>
    <arm_group_label>Placebo - Administered once daily (QD)</arm_group_label>
    <arm_group_label>Placebo - Administered twice daily (BID)</arm_group_label>
    <arm_group_label>Placebo - single dose</arm_group_label>
    <arm_group_label>Placebo -single dose</arm_group_label>
    <arm_group_label>Placebo- single dose</arm_group_label>
    <arm_group_label>Placebo: single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) of 18-29 kg/m2&#xD;
&#xD;
          2. Must agree to use protocol-specified methods of contraception&#xD;
&#xD;
          3. Negative pregnancy test&#xD;
&#xD;
          4. Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding&#xD;
&#xD;
          2. Abuse of alcohol or drugs&#xD;
&#xD;
          3. Use of other investigational drugs within 30 days of dosing&#xD;
&#xD;
          4. Other clinically significant medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>888-481-1607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Administrator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

